Malaria Drug Shortages in Kenya: A Major Failure to Provide Access to Effective Treatment
Malaria Drug Shortages in Kenya: A Major Failure to Provide Access to Effective Treatment
复制标题
DOI：
10.4269/ajtmh.2009.80.737
复制
发表时间：
2009-05-01
影响因子：
3.3
通讯作者：
Snow, Robert W.
中科院分区：
文献类型：
--
作者：
Kangwana, Beth B.;Njogu, Julius;Snow, Robert W.
治疗政策成功实施及其有效性的一个关键基准是在护理点可以获得推荐的药物。在肯尼亚引入蒿甲醚-灭菊碱（AL）用于治疗无并发症的疟疾两年后，我们进行了一项横断面调查，以调查七个疟疾流行区政府机构中 AL 的可用性。接受调查的 4 家机构中有 1 家没有库存 4 种 AL 特定体重治疗包；四分之三的设施中至少有一种特定体重的 AL 包装缺货，导致卫生工作者开出了一系列不合适的替代品。短缺很大程度上是由于采购过程延迟造成的。各国卫生部和国际社会必须解决当前公共部门抗疟药物供应面临的缺陷。
A key bench mark of successful therapeutic policy implementation, and thus effectiveness, is that the recommended drugs are available at the point of care. Two years after artemether-lumefathrine (AL) was introduced for the management of uncomplicated malaria in Kenya, we carried out a cross-sectional survey to investigate AL availability in government facilities in seven malaria-endemic districts. One of four of the surveyed facilities had none of the four AL weight-specific treatment packs in stock; three of four facilities were Out of stock of at least one weight-specific AL pack, leading health workers to prescribe a range of inappropriate alternatives. The shortage was in large part caused by a delayed procurement process. National ministries of health and the international community must address the Current shortcomings facing antimalarial drug supply to the public sector.